ICUI Quote, Financials, Valuation and Earnings

iRhythm Holdings, Inc. has a net margin of -2.91% compared to ICU Medical, Inc.'s net margin of 2.67%. ICU Medical, Inc.'s return on equity of 0.04% beat iRhythm Holdings, Inc.'s return on equity of -40.07%.

ICU Medical, Inc. has a consensus price target of $182.67, signalling upside risk potential of 16.33%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $212.87 which suggests that it could grow by 41.01%. Given that iRhythm Holdings, Inc. has higher upside potential than ICU Medical, Inc., analysts believe iRhythm Holdings, Inc. is more attractive than ICU Medical, Inc..

ICU Medical, Inc. has a beta of 0.794, which suggesting that the stock is 20.551% less volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.245%.

ICU Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.

ICU Medical, Inc. quarterly revenues are $540.3M, which are larger than iRhythm Holdings, Inc. quarterly revenues of $208.9M. ICU Medical, Inc.'s net income of -$15.7M is lower than iRhythm Holdings, Inc.'s net income of $5.6M. Notably, ICU Medical, Inc.'s price-to-earnings ratio is 6,383.33x while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical, Inc. is 1.74x versus 6.52x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems, Inc. has a net margin of -2.91% compared to ICU Medical, Inc.'s net margin of 7.22%. ICU Medical, Inc.'s return on equity of 0.04% beat Merit Medical Systems, Inc.'s return on equity of 8.28%.

ICU Medical, Inc. has a consensus price target of $182.67, signalling upside risk potential of 16.33%. On the other hand Merit Medical Systems, Inc. has an analysts' consensus of $103.64 which suggests that it could grow by 26.06%. Given that Merit Medical Systems, Inc. has higher upside potential than ICU Medical, Inc., analysts believe Merit Medical Systems, Inc. is more attractive than ICU Medical, Inc..

ICU Medical, Inc. has a beta of 0.794, which suggesting that the stock is 20.551% less volatile than S&P 500. In comparison Merit Medical Systems, Inc. has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.827%.

ICU Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical, Inc. pays -- of its earnings as a dividend. Merit Medical Systems, Inc. pays out -- of its earnings as a dividend.

ICU Medical, Inc. quarterly revenues are $540.3M, which are larger than Merit Medical Systems, Inc. quarterly revenues of $384.3M. ICU Medical, Inc.'s net income of -$15.7M is lower than Merit Medical Systems, Inc.'s net income of $27.8M. Notably, ICU Medical, Inc.'s price-to-earnings ratio is 6,383.33x while Merit Medical Systems, Inc.'s PE ratio is 42.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical, Inc. is 1.74x versus 3.38x for Merit Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -2.91% compared to ICU Medical, Inc.'s net margin of -316.61%. ICU Medical, Inc.'s return on equity of 0.04% beat Plus Therapeutics, Inc.'s return on equity of --.

ICU Medical, Inc. has a consensus price target of $182.67, signalling upside risk potential of 16.33%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than ICU Medical, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than ICU Medical, Inc..

ICU Medical, Inc. has a beta of 0.794, which suggesting that the stock is 20.551% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

ICU Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

ICU Medical, Inc. quarterly revenues are $540.3M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. ICU Medical, Inc.'s net income of -$15.7M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, ICU Medical, Inc.'s price-to-earnings ratio is 6,383.33x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical, Inc. is 1.74x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care, Inc. has a net margin of -2.91% compared to ICU Medical, Inc.'s net margin of -0.2%. ICU Medical, Inc.'s return on equity of 0.04% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.

ICU Medical, Inc. has a consensus price target of $182.67, signalling upside risk potential of 16.33%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $27.27 which suggests that it could grow by 10.08%. Given that ICU Medical, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe ICU Medical, Inc. is more attractive than Tandem Diabetes Care, Inc..

ICU Medical, Inc. has a beta of 0.794, which suggesting that the stock is 20.551% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.285%.

ICU Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ICU Medical, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.

ICU Medical, Inc. quarterly revenues are $540.3M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. ICU Medical, Inc.'s net income of -$15.7M is lower than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, ICU Medical, Inc.'s price-to-earnings ratio is 6,383.33x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ICU Medical, Inc. is 1.74x versus 1.63x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.